Eliem Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELYM research report →
Companywww.eliemtx.com
Eliem Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial.
- CEO
- Aoife M. Brennan BAO, BCh, MB, MMSc
- IPO
- 2021
- Employees
- 9
- HQ
- Redmond, WA, US
Price Chart
Valuation
- Market Cap
- $342.68M
- P/E
- -13.59
- P/S
- 0.00
- P/B
- 4.85
- EV/EBITDA
- -12.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -31.46%
- ROIC
- -40.44%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-59,851,000 · 19.01%
- EPS
- $-0.88 · 42.48%
- Op Income
- $-67,883,000
- FCF YoY
- -250.48%
Performance & Tape
- 52W High
- $11.55
- 52W Low
- $2.35
- 50D MA
- $6.46
- 200D MA
- $5.57
- Beta
- -0.38
- Avg Volume
- 519.72K
Get TickerSpark's AI analysis on ELYM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 24 | Pimblett Emily | other | 5,000 |
| Sep 18, 24 | Pimblett Emily | other | 5,000 |
| Sep 20, 24 | Pimblett Emily | sell | 1,182 |
| Sep 20, 24 | Pimblett Emily | sell | 9 |
| Aug 26, 24 | Kaplan Brett | other | 465,000 |
| Aug 26, 24 | Kaplan Brett | other | 77,500 |
| Aug 26, 24 | Kaplan Brett | other | 0 |
| Jul 19, 24 | Morisset Valerie | sell | 10,201 |
| Jul 19, 24 | Morisset Valerie | sell | 50,000 |
| Jul 22, 24 | Morisset Valerie | sell | 39,005 |
Our ELYM Coverage
We haven't published any research on ELYM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ELYM Report →